Last reviewed · How we verify
NCT05175326
Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs
trial in Ovarian Cancer in 64 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 64 |
| Start date | 1 November 2021 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 November 2022 |
| Sites | 1 location across China |
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Organoid — all drugs for Organoid →
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Who can join
Adults 18 to 75, any sex, with Ovarian Cancer or Organoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, observational clinical study that plans to recruit 64 ovarian cancer patients within one year. The purpose of this study is to evaluate the consistency and accuracy of the organoid model derived from patients with ovarian cancer and the patient's clinical medication, so as to predict the clinical efficacy of anti-cancer drugs
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274 -
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5 -
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735 -
Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.
Ciucci A, Buttarelli M, Fagotti A, Scambia G, et al · · 2022 · cited 32× · PMID 35705879 · DOI 10.1007/s00018-022-04395-y -
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656 -
Patient-derived organoid culture in epithelial ovarian cancers-Techniques, applications, and future perspectives.
Chan WS, Mo X, Ip PPC, Tse KY. · · 2023 · cited 11× · PMID 37776168 · DOI 10.1002/cam4.6521 -
Organoids in ovarian cancer: a platform for disease modeling, precision medicine, and drug assessment.
Hu H, Sun C, Chen J, Li Z. · · 2024 · cited 9× · PMID 38509422 · DOI 10.1007/s00432-024-05654-0 -
Organoid development and applications in gynecological cancers: the new stage of tumor treatment.
Li Y, Qin M, Liu N, Zhang C. · · 2025 · cited 6× · PMID 39819668 · DOI 10.1186/s12951-024-03086-z
Verify or expand the search:
- PubMed search for NCT05175326
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials
Trials by the same sponsor.
- NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
- NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
- NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
- NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
- NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05175326 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Last refreshed: 3 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05175326.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing